tetano
Editor, Senior Moderator
Am J Ophthalmol
. 2022 Feb 25;S0002-9394(22)00070-8.
doi: 10.1016/j.ajo.2022.02.011. Online ahead of print.
COVID-19 vaccination and the eye
Michael T M Wang[SUP] 1 [/SUP], Rachael L Niederer[SUP] 1 [/SUP], Charles N J McGhee[SUP] 1 [/SUP], Helen V Danesh-Meyer[SUP] 2 [/SUP]
Affiliations
Abstract
Purpose: To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events.
Design: Narrative literature review.
Methods: The literature search was conducted in August 2021 using four electronic databases (MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic Reviews), and population-based pharmacovigilance surveillance data were retrieved from all governmental agencies participating in the World Health Organization (WHO) Programme for International Drug Monitoring with publicly available online adverse event databases in English.
Results: A small number of case reports have documented uveitis flares and acute corneal graft rejection occurring within the first three weeks following immunisation, while isolated cases of optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted. However, data from population-based pharmacovigilance surveillance systems would suggest that the prevalence of vaccination-associated ocular adverse events are very rare.
Conclusions: Vaccination-associated ocular adverse events are rare, and there is currently no substantive evidence to counterweigh the overwhelming benefits of COVID-19 immunisation in patients with pre-existing ophthalmic conditions.
Keywords: COVID-19; Coronavirus; SARS-CoV-2; cornea; eye; immunosuppression; optic nerve; retina; uveitis; vaccine.
. 2022 Feb 25;S0002-9394(22)00070-8.
doi: 10.1016/j.ajo.2022.02.011. Online ahead of print.
COVID-19 vaccination and the eye
Michael T M Wang[SUP] 1 [/SUP], Rachael L Niederer[SUP] 1 [/SUP], Charles N J McGhee[SUP] 1 [/SUP], Helen V Danesh-Meyer[SUP] 2 [/SUP]
Affiliations
- PMID: 35227700
- DOI: 10.1016/j.ajo.2022.02.011
Abstract
Purpose: To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events.
Design: Narrative literature review.
Methods: The literature search was conducted in August 2021 using four electronic databases (MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic Reviews), and population-based pharmacovigilance surveillance data were retrieved from all governmental agencies participating in the World Health Organization (WHO) Programme for International Drug Monitoring with publicly available online adverse event databases in English.
Results: A small number of case reports have documented uveitis flares and acute corneal graft rejection occurring within the first three weeks following immunisation, while isolated cases of optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted. However, data from population-based pharmacovigilance surveillance systems would suggest that the prevalence of vaccination-associated ocular adverse events are very rare.
Conclusions: Vaccination-associated ocular adverse events are rare, and there is currently no substantive evidence to counterweigh the overwhelming benefits of COVID-19 immunisation in patients with pre-existing ophthalmic conditions.
Keywords: COVID-19; Coronavirus; SARS-CoV-2; cornea; eye; immunosuppression; optic nerve; retina; uveitis; vaccine.